000864920 001__ 864920
000864920 005__ 20210130002753.0
000864920 037__ $$aFZJ-2019-04523
000864920 1001_ $$0P:(DE-HGF)0$$aWerner, J. M.$$b0
000864920 1112_ $$aJahrestagung der Deutschen Gesellschaft für Nuklearmedizin 2019$$cBremen$$d2019-04-03 - 2019-04-06$$wGermany
000864920 245__ $$aDifferentiation of treatment-related changes from tumor progression: A direct comparison between dynamic FET PET and ADC values obtained from DWI MRI
000864920 260__ $$c2019
000864920 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1567686860_30741
000864920 3367_ $$033$$2EndNote$$aConference Paper
000864920 3367_ $$2BibTeX$$aINPROCEEDINGS
000864920 3367_ $$2DRIVER$$aconferenceObject
000864920 3367_ $$2DataCite$$aOutput Types/Conference Abstract
000864920 3367_ $$2ORCID$$aOTHER
000864920 520__ $$aV29Differentiation of treatment-related changes from high-grade glioma progression: A direct comparison between FET PET and ADC values obtained by DWI MRIJ. Werner1, G. Stoffels2, T. Lichtenstein3, J. Borggrefe3, G. Ceccon1, N. J. Shah2, G. R. Fink1, K. J. Langen2, C. Kabbasch3, N. Galldiks11University Hospital Cologne, Dept. of Neurology, Cologne; 2Research Center Jülich, Inst. of Neuroscience and Medicine (INM-4), Jülich; 3University Hospital Cologne, Dept. of Neuroradiology, CologneZiel/Aim:Following brain cancer treatment, the capacity of anatomical MRI to differentiate neoplastic tissue from treatment-related changes such as pseudoprogression is limited. The aim of this study was to compare apparent diffusion coefficient (ADC) values obtained by diffusion-weighted MRI (DWI) with static parameters of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET for the differentiation of treatment-related changes from tumor progression.Methodik/Methods:Forty-eight pretreated high-grade glioma patients (mean age, 50±15 years) with anatomical MRI findings suspicious for tumor progression (median time after completion of last treatment, 16 weeks) were additionally investigated using DWI MRI and FET PET. Maximum and mean tumor-to-brain ratios (TBRmax/mean) of FET uptake were determined (20-40 minutes post-injection). Regions-of-Interest analyses were performed concerning the enhancing lesion on ADC maps calculated from DWI MRI. Diagnoses were confirmed neuropathologically (21%; 10 patients) or clinico-radiologically (79%; 38 patients). Diagnostic performances of TBRs and ADC values for the correct differentiation were evaluated each alone using receiver-operating-characteristic analyses, or the Fisher Exact test for a combinational approach.Ergebnisse/Results:Ten of 48 patients had treatment-related changes (21%). The diagnostic performance of FET PET was clearly higher (threshold TBRmean, 1.95; sensitivity, 100%; specificity, 79%; accuracy, 83%; AUC 0.89±0.05; P-3 mm2/s; sensitivity, 60%; specificity; 79%; accuracy, 75%; AUC 0.73±0.09; P=0.05). The combination of both imaging parameters did not increase the accuracy (64%; P=0.144).Schlussfolgerungen/Conclusions:Static FET PET seems to add valuable clinical information regarding the differentiation of early treatment-related changes from tumor progression and outperforms ADC values for this highly relevant clinical question.
000864920 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000864920 7001_ $$0P:(DE-Juel1)131627$$aStoffels, G.$$b1$$ufzj
000864920 7001_ $$0P:(DE-HGF)0$$aLichtenstein, T.$$b2
000864920 7001_ $$0P:(DE-HGF)0$$aBorggrefe, J.$$b3
000864920 7001_ $$0P:(DE-Juel1)145110$$aLohmann, P.$$b4$$ufzj
000864920 7001_ $$0P:(DE-HGF)0$$aCeccon, G.$$b5
000864920 7001_ $$0P:(DE-Juel1)131794$$aShah, N. J.$$b6$$ufzj
000864920 7001_ $$0P:(DE-Juel1)131720$$aFink, G. R.$$b7$$ufzj
000864920 7001_ $$0P:(DE-Juel1)131777$$aLangen, K. J.$$b8$$ufzj
000864920 7001_ $$0P:(DE-HGF)0$$aKabbasch, C.$$b9
000864920 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, N.$$b10$$ufzj
000864920 8564_ $$uhttps://www.nuklearmedizin.de/jahrestagungen/abstr_online2019/abstract_detail.php?navId=227&aId=49
000864920 909CO $$ooai:juser.fz-juelich.de:864920$$pVDB
000864920 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131627$$aForschungszentrum Jülich$$b1$$kFZJ
000864920 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145110$$aForschungszentrum Jülich$$b4$$kFZJ
000864920 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131794$$aForschungszentrum Jülich$$b6$$kFZJ
000864920 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b7$$kFZJ
000864920 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b8$$kFZJ
000864920 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b10$$kFZJ
000864920 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000864920 9141_ $$y2019
000864920 920__ $$lyes
000864920 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000864920 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000864920 980__ $$aabstract
000864920 980__ $$aVDB
000864920 980__ $$aI:(DE-Juel1)INM-3-20090406
000864920 980__ $$aI:(DE-Juel1)INM-4-20090406
000864920 980__ $$aUNRESTRICTED